NTRK1 and renal cell carcinoma: Starting from 2015, the treatment of advanced RCC underwent a second revolution with the advent of immune checkpoint inhibitors, especially agents targeting the programmed cell death-1 receptor, as well as with the advent of new generation tyrosine-kinase receptor inhibitors.